MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. L. Cookies are used to offer you a better browsing experience and to analyze our traffic. com. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. We currently market prescription products for people with. By continuing to use our service, you agree to our use of cookies. View real-time stock prices and stock quotes for a full financial overview. S. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. - Cash, bonds and money market funds of US$22. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share. 68 to a day high of $1. com 10/16/2023. Theratechnologies Inc. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. 00. stock news by MarketWatch. com uses cookies on this site. MONTREAL, Sept. Register for your free account today at data. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. Stockhouse. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. 23 to a day high of $1. Theratechnologies inc. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. 4% from the stock's current price. Stockhouse. In 2022, THTX's revenue was 80. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. was a. Follow. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. European Headquarters. Stockhouse. GlobeNewswire. Theratechnologies's earnings have been declining at an average annual rate of -35. Competitors: Unknown. Stockhouse. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. Company Type For Profit. M. org. We changed the address of the Stockhouse website from to stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. Herein, we report. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Further. With the company starting 2023 with 8,725 employees, that’s an 11. We also use them to share usage. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. We currently market. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. . Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. MONTREAL, Jan. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Katana shareholders will. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. S. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Who is Theratechnologies. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Share your ideas and get valuable. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. 46. -986. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Theratechnologies last announced its earnings data on September 26th, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 1-438. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. We also use them to share usage. 9 million, adjusted EBITDA of $2. 's motion for leave to commence. (TH. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. (882) posted 3 minutes ago. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. 82 million. B2Gold Declares Fourth Quarter 2023 Dividend. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. 124. TH | February 28, 2023. . 33. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. MONTREAL, Aug. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. 521. 65 per cent to C$1. com. Cookies are used to offer you a better browsing experience and to analyze our traffic. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 25 to $1. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. TH | September 26, 2023. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Appoints New Board Member. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. 17% from a day low at $1. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. By continuing to use our service, you agree to our use of cookies. T. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Stockhouse. Stockhouse. VANCOUVER, British Columbia, Nov. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Get the latest Sernova Corp (SVA) real. com uses cookies on this site. Theratechnologies inc. com uses cookies on this site. 49%) At close: 04:00PM EST 1. com uses cookies on this site. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Currency in USD Follow 2W 10W 9M 1. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. FY2023 revenue guidance range set between $90 million and $95 million. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. 514-336-7800. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. For investor inquiries: Leah Gibson. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. communications@theratech. Further. 71%. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 03) EPS for the quarter, beating the consensus estimate of ($0. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Theratechnologies Inc. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Message Board Total Posts: 4. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. THERATECHNOLOGIES INC. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Image source: The Motley Fool. US Headquarters. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. ET. Browse posts by Sector and Subsector. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. US Headquarters. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. com uses cookies on this site. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). Once expert advice is considered, the Company. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. European Headquarters. Theratechnologies had a negative net margin of 36. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. By continuing to use our service, you agree to our use of cookies. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. THERATECHNOLOGIES INC. THTX | Complete Theratechnologies Inc. The Theratechnologies Inc. lgibson. Losses were -47. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. These pharmaceuticals. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. L. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. This news release constitutes a “designated news release” for the purposes of the Company’s. 8 million. By continuing to use our service, you agree to our use of cookies. We currently market prescription products for people with HIV in the United States. T. 67% from the latest price. 9%, while the Biotechs industry saw earnings growing at 17. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Stockhouse. 86%. . com uses cookies on this site. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ir@theratech. Remember, high Theratechnologies' alpha is almost always a sign of. MONTREAL, Feb. 0. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. Cookies are used to offer you a better browsing experience and to. T. Trogarzo® and. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. stock news by MarketWatch. T. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. Watch list NEW Set a price target alert After Hours Last. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. 00%. 28 $1. Forecast to breakeven in 2024 Jul 15. We currently market prescription products for people with HIV in the United States. MONTREAL, Jan. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. com. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. Stockhouse. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. By continuing to use our service, you agree to our use of cookies. MONTREAL, Jan. D. 3. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock news by MarketWatch. MONTREAL, Oct. We currently market prescription products for people with HIV in the United States. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. 4 million. Patient assistance: 833-238-4372. is a pharmaceutical company. C. 00. -based clinical sites participating in the conduct of the Phase. By continuing to use our service, you agree to our use of cookies. com. Theratechnologies Inc. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. During the last trading day the stock fluctuated 12. Theratechnologies Inc. 25. Q4 2022 consolidated revenue growth of 14. com uses cookies on this site. FAQ – Émetteurs inscrits NOUVEAU. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . MONTREAL, Aug. com uses cookies on this site. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Montreal-based biopharmaceutical company Theratechnologies Inc. com uses cookies on this site. Elif McDonald - Senior Director, Investor Relations. Headquarters. m. The company reported ($0. Montréal, Québec, Canada . (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. 9 million as at August 31, 2023. View real-time stock prices and stock quotes for a full financial overview. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (882) posted 3 minutes ago. By continuing to use our service, you agree to our use of cookies. A high-level overview of Theratechnologies Inc. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. The abstract and poster can be found on Theratechnologies’ website. [email protected] Inc: Overview. R. com. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. Their THTX share price targets range from $36. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 2% for this period. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Senior Director, Investor Relations. znewcar1. Stockhouse. 6. FDA for its IV push form of administration of Trogarzo. -4. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. The FDA granted fast track designation to TH1902 as a single agent for. Shares of Theratechnologies are up 4. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Aug. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Cookies are used to offer you a better browsing experience and to analyze our traffic. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. (THTX) NasdaqCM - NasdaqCM Real Time Price. . By continuing to use our service, you agree to our use of cookies. TORONTO, May 19, 2023. This news release constitutes a “designated news release” for the purposes. TORONTO, Sept. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . OTCQX – this is the premium tier of OTC stocks. Theratechnologies Announces 1-for-4 Reverse Stock Split. Jours fériés des marchés. 89 $2. Theratechnologies Inc. 9% more than in 2021. com. 1M. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. We also use them to share usage. 81 million for the quarter. 617-356-1009. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. These companies provide a lot of detail to the OTC Markets Group including audited financials. Stockhouse. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. com uses cookies on this site. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Biopharmaceutical company Theratechnologies Inc. GUD | Complete Knight Therapeutics Inc. Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. 4%. 5% workforce reduction. We currently market prescription products for people with HIV in the United States. com uses cookies on this site. 81 million for the quarter. Theratechnologies Inc. TH 48% v4,15M c1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 1-514-336-7800. com uses cookies on this site. com uses cookies on this site. Senior Director, Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. m. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 20% from a day low at $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. Contact Email communications@theratech. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. Betteryear2. com. This news release constitutes a “designated news release” for the purposes of the Company’s. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. com. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. NCU. MONTREAL, Feb.